MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zoll Acquires TherOx for Undisclosed Sum

TherOx received FDA approval for its SuperSaturated Oxygen (SSO2) Therapy in April.

Fresh off receiving a PMA, TherOx is now in the process of being acquired by Zoll Medical, an Asahi Kasei Group Company.  Additional terms of the deal were not disclosed.

Irvine, CA-based TherOX is focused on improving the treatment of acute myocardial infarction, and markets systems to deliver SuperSaturated Oxygen (SSO2) Therapy. The therapy has been demonstrated to reduce infarct size after primary coronary intervention (PCI) with stenting in patients with left anterior descending ST-elevation myocardial infarction.

When a large ischemic area of muscle damage remains following AMI, the patient condition often deteriorates into debilitating heart failure. The SuperSaturated Oxygen (SSO2) Therapy was greenlit in April and made MD+DI’s list for recent FDA-approved technologies.

"Zoll and TherOx are both focused on emergency cardiac care," Neil Johnston, president of Zoll Circulation, said in a release. "This acquisition expands the Zoll product portfolio in support of excellence for patients and caregivers. No delay in door-to-balloon times and improved clinical outcomes is a combination we think physicians will find appealing. Because SSO Therapy is delivered following PCI and stenting, there is no disruption of today’s workflow in the cath lab.”

Filed Under
500 characters remaining